Radiogenomic predictors of treatment response in head and neck squamous cell carcinoma
头颈鳞状细胞癌治疗反应的放射基因组预测因子
基本信息
- 批准号:10879183
- 负责人:
- 金额:$ 22.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-07 至 2024-04-14
- 项目状态:已结题
- 来源:
- 关键词:AddressAftercareCancer ModelClinicalData SetDisease ProgressionEarly identificationEnsureEpidermal Growth Factor ReceptorFutureGene ExpressionGenomicsGoalsHPV-negative head and neck cancerHead and Neck Squamous Cell CarcinomaHuman PapillomavirusHypoxia PathwayImageKansasMAP Kinase GeneMeasuresMediatingModelingMutationOperative Surgical ProceduresOutcomePapillomavirusPatientsPhenotypePrecision therapeuticsPrediction of Response to TherapyPrognostic MarkerProgression-Free SurvivalsProtein KinaseRadiogenomicsSamplingTissue MicroarrayTumor-Derivedbiobankbiomarker validationcancer imagingchemoradiationcommunity engagementcontrast enhanced computed tomographydesigngenomic biomarkerhigh riskpatient biomarkerspatient engagementpatient orientedprecision medicineprognosticprognostic modelradiological imagingradiomicstreatment responsetumor
项目摘要
Despite recent advances in treatment of head and neck squamous cell carcinoma (HNSCC), five-year
overall survival (OS) has remained poor due to high rates of disease progression after treatment. A lack of
reliable prognostic biomarkers limits ability to predict disease progression in non-human papillomavirus
(HPV) mediated HNSCC. Among candidates for salvage surgery in the setting of disease progression after
primary chemoradiotherapy, 5-year OS is estimated at just 16%. Radiomics, involving analysis of large
numbers of quantitative tumor imaging features, has been used to develop image-based prognostic
models. Delta radiomics incorporates differences between pre- and post-treatment images, thereby
capturing quantitative measures of treatment response. To address critical need for prognostic biomarkers
for patients with HNSCC, we aim to develop and validate radiogenomic models to predict 2-year overall
and progression-free survival using tumor-derived genomic biomarkers and delta radiomic features derived
from pre- and post-treatment contrast-enhanced computed tomography. Prior studies developed highly
accurate models of cancer treatment response using delta radiomics, but not in patients with locoregionally
advanced HNSCC. Few studies have evaluated reliable and concordant genomic and radiomic prognostic
phenotypes in HNSCC. We hypothesize that a multi-‘omic model integrating radiogenomic features will
accurately predict 2-year overall and progression-free survival. We aim to 1) develop a fully annotated,
patient-centered, clinical outcome and radiographic dataset with associated tumor samples for patients with
locoregionally advanced HPV-negative HNSCC treated with definitive chemoradiotherapy and 2) develop
radiogenomic models to predict 2-year OS and PFS using tumor-derived genomic biomarkers and delta
radiomic features derived from pre- and post-treatment contrast-enhanced computed tomography. We will
engage the Quantitative ‘Omics Core to extract radiomic features and explore radiogenomic phenotypes
associated with 2-year OS and PFS. We will use the Biobanking and Biomarker Validation core to generate
a HNSCC patient-derived tissue microarray to identify mutations and quantify gene expression relevant to
epidermal growth factor receptor, MAPK-associated protein kinase 2 (MK2) and hypoxia pathways. With
the Patient and Community Engagement core, we will ensure that patient priorities are consistently
represented in the design. Long-term goal is to support future trials aimed at early identification of patients
at high-risk of disease progression who are likely to benefit from precision treatment approaches.
尽管最近在头颈部鳞状细胞癌(HNSCC)的治疗方面取得了进展,
由于治疗后疾病进展率高,总生存期(OS)仍然很差。缺乏
可靠的预后生物标志物限制了预测非人乳头瘤病毒疾病进展的能力
(HPV)介导的HNSCC。在治疗后疾病进展的情况下进行挽救手术的候选人中,
在初次放化疗中,5年OS估计仅为16%。放射组学,包括分析大的
许多定量肿瘤成像特征,已被用于开发基于图像的预后
模型Delta放射组学结合了治疗前和治疗后图像之间的差异,
捕获治疗反应的量化指标。解决对预后生物标志物的迫切需求
对于HNSCC患者,我们的目标是开发和验证放射基因组学模型,以预测2年的总体
使用肿瘤衍生的基因组生物标志物和衍生的δ放射组学特征
对比增强计算机断层扫描的结果先前的研究高度发达
使用delta放射组学的癌症治疗反应的准确模型,但不是在局部区域性的患者中
晚期HNSCC很少有研究评估可靠和一致的基因组和放射组预后
HNSCC中的表型。我们假设,一个多组学模型整合放射基因组学特征,
准确预测2年总体和无进展生存期。我们的目标是:1)开发一个完整的注释,
以患者为中心的临床结局和放射学数据集,以及患者的相关肿瘤样本
局部晚期HPV阴性HNSCC接受确定性放化疗治疗,2)发生
放射基因组学模型,使用肿瘤源性基因组生物标志物和Δ预测2年OS和PFS
来自治疗前和治疗后对比度增强计算机断层扫描的放射组学特征。我们将
利用定量组学核心提取放射组学特征并探索放射基因组学表型
与2年OS和PFS相关。我们将使用生物库和生物标志物验证核心来生成
HNSCC患者来源的组织微阵列,以鉴定突变并量化与以下相关的基因表达:
表皮生长因子受体、MAPK相关蛋白激酶2(MK2)和缺氧途径。与
病人和社区参与的核心,我们将确保病人的优先事项是一致的,
在设计中表现出来。长期目标是支持旨在早期识别患者的未来试验
疾病进展的高风险人群,他们可能会从精确治疗方法中受益。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andres Martin Bur其他文献
Andres Martin Bur的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andres Martin Bur', 18)}}的其他基金
Automated Detection and Classification of Laryngeal Diseases Using Deep Neural Networks
使用深度神经网络自动检测和分类喉部疾病
- 批准号:
10043172 - 财政年份:2020
- 资助金额:
$ 22.95万 - 项目类别:
相似海外基金
Life outside institutions: histories of mental health aftercare 1900 - 1960
机构外的生活:1900 - 1960 年心理健康善后护理的历史
- 批准号:
DP240100640 - 财政年份:2024
- 资助金额:
$ 22.95万 - 项目类别:
Discovery Projects
Development of a program to promote psychological independence support in the aftercare of children's homes
制定一项计划,促进儿童之家善后护理中的心理独立支持
- 批准号:
23K01889 - 财政年份:2023
- 资助金额:
$ 22.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10452217 - 财政年份:2022
- 资助金额:
$ 22.95万 - 项目类别:
Integrating Smoking Cessation in Tattoo Aftercare
将戒烟融入纹身后护理中
- 批准号:
10670838 - 财政年份:2022
- 资助金额:
$ 22.95万 - 项目类别:
Aftercare for young people: A sociological study of resource opportunities
年轻人的善后护理:资源机会的社会学研究
- 批准号:
DP200100492 - 财政年份:2020
- 资助金额:
$ 22.95万 - 项目类别:
Discovery Projects
Creating a National Aftercare Strategy for Survivors of Pediatric Cancer
为小儿癌症幸存者制定国家善后护理策略
- 批准号:
407264 - 财政年份:2019
- 资助金额:
$ 22.95万 - 项目类别:
Operating Grants
Aftercare of green infrastructure: creating algorithm for resolving human-bird conflicts
绿色基础设施的善后工作:创建解决人鸟冲突的算法
- 批准号:
18K18240 - 财政年份:2018
- 资助金额:
$ 22.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an aftercare model for children who have experienced invasive procedures
为经历过侵入性手术的儿童开发善后护理模型
- 批准号:
17K12379 - 财政年份:2017
- 资助金额:
$ 22.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of a Comprehensive Aftercare Program for children's self-reliance support facility
为儿童自力更生支持设施制定综合善后护理计划
- 批准号:
17K13937 - 财政年份:2017
- 资助金额:
$ 22.95万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Project#2 Extending Treatment Effects Through an Adaptive Aftercare Intervention
项目
- 批准号:
8742767 - 财政年份:2014
- 资助金额:
$ 22.95万 - 项目类别: